Is 2024 the Year for Psychedelic Medicine?
MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.
Source: pharmacytimes.com
Mark Bleackley News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mark Bleackley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mark Bleackley Today - Breaking & Trending Today
Navigating Research in Psychedelics: Investigators Face a Mosaic of Regulations, False Perceptions, and Therapeutic Potential
If clinical trials continue to show that psychedelics offer safe and long-lasting results, then psychedelic-assisted therapy could flourish as a treatment in the mental health space.
Source: pharmacytimes.com
IHL-675A: Advancing Towards Innovative Arthritis Solutions, with Mark Bleackley, PhD
Mark Bleackley, PhD, discusses the upcoming phase 2 trial of IHL-675A designed to explore arthritis treatment through dual-drug comparison, promising global expansion, and its impact on patients’ pain relief.
Source: hcplive.com
IHL-675A Reveals Promising Safety and Pharmacokinetic Profile, with Mark Bleackley, PhD
Results demonstrated IHL-675A was well-tolerated, with no concerning adverse events or serious adverse events reported.
Source: hcplive.com
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 -- Incannex Healthcare Inc. , , a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine...
Source: marketscreener.com